Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
A paramedic prepares plasma for emergency transfusion inside an ambulance as Velico Medical develops Frontline On Demand Plasma for prehospital trauma care, disaster response and military medicine. Representative image.
Pharma & Biotech

Can Velico’s spray-dried plasma move lifesaving transfusion beyond trauma centres?

Frontline On Demand Plasma could bring plasma transfusion closer to ambulances, disaster zones and military front lines, but clinical and regulatory hurdles remain.

Read More
A gastroenterologist reviews inflammatory bowel disease imaging and oral treatment options as cAMPfield Therapeutics advances prifemilast for ulcerative colitis and Crohn’s disease. Representative image.
Pharma & Biotech

cAMPfield launches with $180m as prifemilast enters the crowded IBD race

cAMPfield Therapeutics is backing prifemilast as a better-tolerated oral PDE4 inhibitor for inflammatory bowel disease, but mid-stage trials must prove that selectivity translates into durable remission.

Read More
A healthcare professional administers a seasonal influenza vaccine to an older adult as Moderna’s MFLUSIVA moves closer to a potential United States approval. Representative image.
Pharma & Biotech

Is mRNA-1010 the breakthrough Moderna needs beyond COVID-19 vaccines?

Moderna’s mRNA-1010 has cleared a major regulatory hurdle, but evidence in older adults, higher reactogenicity and seasonal contracting could limit its early impact.

Read More
A neurologist reviews brain MRI and EEG data as uniQure’s AMT-260 gene therapy is investigated as a potential one-time treatment for drug-resistant temporal lobe epilepsy. Representative image.
Pharma & Biotech

Can uniQure’s AMT-260 gene therapy become an alternative to epilepsy surgery?

Explore whether uniQure’s AMT-260 gene therapy can rival epilepsy surgery after early seizure reductions in a small first-in-human cohort.

Read More
A retinal specialist reviews advanced eye scans as Memento Medicines develops MMT-205 to challenge established treatments for wet age-related macular degeneration and diabetic macular edema. Representative image.
Pharma & Biotech

Memento Medicines launches with $93m, but can MMT-205 challenge retinal drug leaders?

Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.

Read More
Representative image of a cancer infusion clinic, reflecting Sanofi’s Sarclisa subcutaneous approval in Japan and the shift toward less burdensome multiple myeloma treatment delivery.
Pharma & Biotech

Could Sanofi’s Sarclisa SC approval change how Japan treats multiple myeloma?

Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!

Read More
Representative image of a neurology consultation with brain scan review, reflecting coverage of uniQure’s AMT-260 gene therapy data and its potential role in refractory mesial temporal lobe epilepsy treatment.
Pharma & Biotech

Why AMT-260’s early epilepsy data could shape the next test for brain-delivered gene therapy

Find out how uniQure’s AMT-260 early epilepsy data could shape the next test for brain-delivered gene therapy.

Read More
Representative image: Kovina Therapeutics’ HPV16 E6-targeted research explores whether restoring p53 activity could open a new precision treatment pathway for HPV16-driven cancers and precancerous disease.
Pharma & Biotech

Can Kovina Therapeutics turn HPV16 E6 from an undruggable viral protein into a cancer target?

See how Kovina Therapeutics’ HPV16 E6 inhibitors restore p53 in preclinical models and what must happen before human trials.

Read More
Representative image of an oncology consultation, reflecting coverage of Context Therapeutics’ CTIM-76 Phase 1 data and its potential role in platinum-resistant ovarian cancer treatment.
Pharma & Biotech

Why CTIM-76’s early ovarian cancer data could sharpen interest in CLDN6 T cell engagers

Find out how CTIM-76’s early Phase 1 data could shape CLDN6 T cell engager development in platinum-resistant ovarian cancer.

Read More
Representative image: A pediatric diabetes specialist reviews glucose data during an infusion visit as Sanofi’s Tzield expands into newly diagnosed stage 3 type 1 diabetes care.
Pharma & Biotech

Why Sanofi’s Tzield expansion changes the treatment window for type 1 diabetes

Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.

Read More